128 related articles for article (PubMed ID: 12039880)
1. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims.
Smith HJ; Nichol KA; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2002 Jun; 49(6):893-5. PubMed ID: 12039880
[No Abstract] [Full Text] [Related]
2. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
Onodera Y; Uchida Y; Tanaka M; Sato K
J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
[TBL] [Abstract][Full Text] [Related]
4. [Gene sequencing analysis of DNA gyrase and topoisomerase IV as levofloxacin resistance in Streptococcus pneumoniae].
Miyamoto H; Murase M
Kansenshogaku Zasshi; 2002 Oct; 76(10):898-9. PubMed ID: 12448851
[No Abstract] [Full Text] [Related]
5. An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniae.
Alonso R; Galimand M; Courvalin P
J Antimicrob Chemother; 2004 Apr; 53(4):682-3. PubMed ID: 15014061
[No Abstract] [Full Text] [Related]
6. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
7. Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.
Leo E; Gould KA; Pan XS; Capranico G; Sanderson MR; Palumbo M; Fisher LM
J Biol Chem; 2005 Apr; 280(14):14252-63. PubMed ID: 15659402
[TBL] [Abstract][Full Text] [Related]
8. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Mitton-Fry MJ; Brickner SJ; Hamel JC; Brennan L; Casavant JM; Chen M; Chen T; Ding X; Driscoll J; Hardink J; Hoang T; Hua E; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Plotkin M; Reilly U; Robinson S; Schafer J; Shepard RM; Smith JF; Stone GG; Subramanyam C; Yoon K; Yuan W; Zaniewski RP; Zook C
Bioorg Med Chem Lett; 2013 May; 23(10):2955-61. PubMed ID: 23566517
[TBL] [Abstract][Full Text] [Related]
9. Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.
Fisher LM; Pan XS
Methods Mol Med; 2008; 142():11-23. PubMed ID: 18437302
[TBL] [Abstract][Full Text] [Related]
10. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
[TBL] [Abstract][Full Text] [Related]
11. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
12. Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.
Dupont P; Aubry A; Cambau E; Gutmann L
J Bacteriol; 2005 Feb; 187(4):1536-40. PubMed ID: 15687222
[TBL] [Abstract][Full Text] [Related]
13. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.
Park HS; Jung SJ; Kwak JH; Choi DR; Choi EC
Int J Antimicrob Agents; 2010 Jul; 36(1):97-8. PubMed ID: 20403681
[No Abstract] [Full Text] [Related]
14. Dual activity of fluoroquinolones against Streptococcus pneumoniae.
Fisher LM; Heaton VJ
J Antimicrob Chemother; 2003 Feb; 51(2):463-4; author reply 464-5. PubMed ID: 12562724
[No Abstract] [Full Text] [Related]
15. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
Morrissey I; George J
Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
[TBL] [Abstract][Full Text] [Related]
16. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
[TBL] [Abstract][Full Text] [Related]
17. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Weigel LM; Anderson GJ; Facklam RR; Tenover FC
Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of and resistance to quinolones.
Bearden DT; Danziger LH
Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
[TBL] [Abstract][Full Text] [Related]
19. Activity of and resistance to moxifloxacin in Staphylococcus aureus.
Ince D; Zhang X; Hooper DC
Antimicrob Agents Chemother; 2003 Apr; 47(4):1410-5. PubMed ID: 12654680
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
